InterCure shares are trading higher after the company announced a final settlement with Israeli tax authorities, securing $77 million in compensation for indirect damages from the October 7 attacks and subsequent war.

InterCure Announces Final Settlement With Israeli Tax Authorities, Compensation Fund For About $77M In Indirect War Damages

InterCure Announces 1-For-5 Reverse Stock Split, Effective August 24

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds

InterCure Ltd. announced a binding term sheet for NIS 22 million (approximately US$7.4 million) in private placement financing, with potential to increase to NIS 54 million. The funding includes investments from CEO Alexander Rabinovich and leading pharma-focused hedge funds including Bennu Pharma Fund Ltd. The company plans to use proceeds for global expansion, particularly in Germany and U.S. regulated medical cannabis markets, as well as recovery and expansion of its Nir Oz facility.